EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Traumatic Brain Injury - Pipeline Review, H1 2017

  • ID: 4091077
  • Report
  • February 2017
  • 259 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ALSP Inc
  • Cognosci Inc
  • Neuralstem Inc
  • Omeros Corp
  • QR Pharma Inc
  • SynZyme Technologies LLC
  • MORE
Traumatic Brain Injury - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ALSP Inc
  • Cognosci Inc
  • Neuralstem Inc
  • Omeros Corp
  • QR Pharma Inc
  • SynZyme Technologies LLC
  • MORE
Introduction

Traumatic Brain Injury - Overview

Traumatic Brain Injury - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Traumatic Brain Injury - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Traumatic Brain Injury - Companies Involved in Therapeutics Development

ALSP Inc

Amarantus Bioscience Holdings Inc

Apollo Endosurgery Inc

Athersys Inc

Beech Tree Labs Inc

Cognosci Inc

Eustralis Pharmaceuticals Ltd

Intellect Neurosciences Inc

International Stem Cell Corp

Ischemix Inc

Karyopharm Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Levolta Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

MandalMed Inc

Mapreg SAS

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

NeuroNascent Inc

NeuroVive Pharmaceutical AB

New World Laboratories Inc

NuvOx Pharma LLC

Omeros Corp

Oxeia Biopharmaceuticals Inc

PharmatrophiX Inc

Phylogica Ltd

Prevacus Inc

QR Pharma Inc

RegeneRx Biopharmaceuticals Inc

Remedy Pharmaceuticals Inc

Sage Therapeutics Inc

SanBio Inc

STATegics Inc

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

Tetra Discovery Partners LLC

Thera Neuropharma Inc

vasopharm GmbH

VG Life Sciences Inc

Traumatic Brain Injury - Drug Profiles

(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile

2-DG - Drug Profile

ALP-496 - Drug Profile

AMRS-001 - Drug Profile

AST-002 - Drug Profile

AST-004 - Drug Profile

AVL-8168 - Drug Profile

BQ-A - Drug Profile

brexanolone - Drug Profile

BTL-slo - Drug Profile

Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile

CEVA-101 - Drug Profile

CEVA-102 - Drug Profile

CHEC-9 - Drug Profile

CMX-2043 - Drug Profile

CNB-001 - Drug Profile

COG-1410 - Drug Profile

cyclosporine - Drug Profile

dexamethasone acetate + melatonin - Drug Profile

EPO-Variant - Drug Profile

EUC-001 - Drug Profile

felbamate - Drug Profile

glyburide - Drug Profile

HBI-002 - Drug Profile

HBI-137 - Drug Profile

HBN-1 - Drug Profile

HBN-2 - Drug Profile

HPI-201 - Drug Profile

HPI-363 - Drug Profile

ibudilast - Drug Profile

ICCN-100 - Drug Profile

ISC-hpNSC - Drug Profile

JM-4 - Drug Profile

KPT-350 - Drug Profile

LB-201 - Drug Profile

LB-205 - Drug Profile

LM-22A4 - Drug Profile

LM11A-31BHS - Drug Profile

Lpathomab - Drug Profile

MAP-4343 - Drug Profile

Monoclonal Antibody for Central Nervous System - Drug Profile

Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile

Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile

MW-151 - Drug Profile

N-acetyl cysteine amide - Drug Profile

ND-478 - Drug Profile

Neu-2000 - Drug Profile

neuregulin-1 - Drug Profile

NFx-101 - Drug Profile

NNI-370 - Drug Profile

NNZ-2591 - Drug Profile

NSI-189 - Drug Profile

NSI-566 - Drug Profile

NVX-108 - Drug Profile

NVX-428 - Drug Profile

NWL-53 - Drug Profile

NYX-2925 - Drug Profile

OXE-103 - Drug Profile

PEG-HCC - Drug Profile

PF-05285401 - Drug Profile

Posiphen - Drug Profile

PRV-002 - Drug Profile

PYC-35 - Drug Profile

PYC-36 - Drug Profile

PYC-38 - Drug Profile

PYC-98 - Drug Profile

R-554 - Drug Profile

RGN-352 - Drug Profile

ronopterin - Drug Profile

SanFlow - Drug Profile

SB-623 - Drug Profile

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile

Small Molecules for Traumatic Brain Injury - Drug Profile

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile

Stem Cell Therapy for Central Nervous System Disorders - Drug Profile

STSE-15 - Drug Profile

SYN-2 - Drug Profile

SYN-NCE - Drug Profile

T-094 - Drug Profile

TauC-3 - Drug Profile

UH-0113 - Drug Profile

UH-0213 - Drug Profile

VG-1177 - Drug Profile

VitalHeme - Drug Profile

VOLT-02 - Drug Profile

XN-001 - Drug Profile

ZL-006 - Drug Profile

Traumatic Brain Injury - Dormant Projects

Traumatic Brain Injury - Discontinued Products

Traumatic Brain Injury - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Traumatic Brain Injury, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Companies, H1 2017 (Contd..3), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1 2017 (Contd..2), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Traumatic Brain Injury - Pipeline by ALSP Inc, H1

Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1

Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H1

Traumatic Brain Injury - Pipeline by Athersys Inc, H1

Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1

Traumatic Brain Injury - Pipeline by Cognosci Inc, H1

Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1

Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1

Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1

Traumatic Brain Injury - Pipeline by Ischemix Inc, H1

Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1

Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1

Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1

Traumatic Brain Injury - Pipeline by MandalMed Inc, H1

Traumatic Brain Injury - Pipeline by Mapreg SAS, H1

Traumatic Brain Injury - Pipeline by Neuralstem Inc, H1

Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1

Traumatic Brain Injury - Pipeline by Neurofx Inc, H1

Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1

Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1

Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1

Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1

Traumatic Brain Injury - Pipeline by Omeros Corp, H1

Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H1

Traumatic Brain Injury - Pipeline by Phylogica Ltd, H1

Traumatic Brain Injury - Pipeline by Prevacus Inc, H1

Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1

Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1

Traumatic Brain Injury - Pipeline by SanBio Inc, H1

Traumatic Brain Injury - Pipeline by STATegics Inc, H1

Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1

Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1

Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1

Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H1

Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1

Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1

Traumatic Brain Injury - Dormant Projects, H1

Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..1), H1

Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..2), H1

Traumatic Brain Injury - Discontinued Products, H1

List of Figures:

Number of Products under Development for Traumatic Brain Injury, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • ALSP Inc
  • Amarantus Bioscience Holdings Inc
  • Apollo Endosurgery Inc
  • Athersys Inc
  • Beech Tree Labs Inc
  • Cognosci Inc
  • Eustralis Pharmaceuticals Ltd
  • Intellect Neurosciences Inc
  • International Stem Cell Corp
  • Ischemix Inc
  • Karyopharm Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Levolta Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • MandalMed Inc
  • Mapreg SAS
  • Neuralstem Inc
  • Neuren Pharmaceuticals Ltd
  • Neurofx Inc
  • NeuroNascent Inc
  • NeuroVive Pharmaceutical AB
  • New World Laboratories Inc
  • NuvOx Pharma LLC
  • Omeros Corp
  • Oxeia Biopharmaceuticals Inc
  • PharmatrophiX Inc
  • Phylogica Ltd
  • Prevacus Inc
  • QR Pharma Inc
  • RegeneRx Biopharmaceuticals Inc
  • Remedy Pharmaceuticals Inc
  • Sage Therapeutics Inc
  • SanBio Inc
  • STATegics Inc
  • Stemedica Cell Technologies Inc
  • SynZyme Technologies LLC
  • Tetra Discovery Partners LLC
  • Thera Neuropharma Inc
  • vasopharm GmbH
  • VG Life Sciences Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll